Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of Clinical Psychiatry.
Patients with bipolar disorder who have a high number of genes linked to schizophrenia are less likely to improve with lithium treatment, according to a newly published study.
The U.S. Food and Drug Administration has approved Otsuka Pharmaceutical Co Ltd's Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States.
Long-term use of benzodiazepine and nonbenzodiazepine hypnotics grew significantly in the United States between 1999 and 2014 apart from demographic shifts, according to a study published online in Psychiatric Services.
Presynaptic dopamine dysfunction is associated with psychosis across diagnostic categories and is a potential drug target for both bipolar disorder and schizophrenia, researchers say.